Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Celestica Inc (CLS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Celestica Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while Celestica Inc trades at $352.02 (market cap $39.70B). The key difference: Celestica Inc is far larger — about 8.8× ACADIA Pharmaceuticals Inc.'s market cap. Which is the better fit depends on your goals.
| ACAD | CLS | |
|---|---|---|
Market Cap | $4.49B | $39.70B |
Sector | Health | Technology |
52-Week High | $28.06 | $472.40 |
52-Week Low | $20.06 | $155.70 |
Enterprise Value | $3.69B | $40.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Celestica (CLS) trades at $350.20, up 4.16% over 24 hours, with a bearish technical signal and neutral oscillators. The company shows strong fundamental momentum with three consecutive quarterly EPS beats and robust profitability metrics, including a 52.45% ROE. Recent leadership appointments in cloud solutions and positive analyst coverage highlight growth potential amid competitive pressures.
The stock presents a compelling growth opportunity with a consensus price target of $440.10, implying 25% upside, supported by AI and data center demand. Key risks include margin pressures, technical bearish signals, and reliance on execution amid industry competition. Investors should weigh strong earnings trajectory against near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Celestica Inc
Celestica provides supply chain and manufacturing solutions for global technology companies. It specializes in high-complexity assembly and platform solutions for AI data centers, aerospace, and medical markets.
Read more on CLS →
